Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 242 entries
View as:

Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02769104 Org: User:
Start: 05/31/16 End: 12/31/19 Due: 12/31/20

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01688700 Org: User:
Start: 09/30/12 End: 09/30/17 Due: 09/30/18

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Phase: N/A Priority: Normal
NCT ID: NCT06195683 Org: User:
Start: 12/01/23 End: 06/20/25 Due: 06/20/26

Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03973008 Org: User:
Start: 03/11/19 End: 05/31/25 Due: 05/31/26

Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone

Phase: N/A Priority: Normal
NCT ID: NCT06173466 Org: User:
Start: 12/15/23 End: 05/30/24 Due: 05/30/25

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Phase: N/A Priority: Normal
NCT ID: NCT02597868 Org: User:
Start: 01/31/13 End: 07/31/17 Due: 07/31/18

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Phase: N/A Priority: Normal
NCT ID: NCT03213587 Org: User:
Start: 07/01/17 End: 07/31/20 Due: 07/31/21

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT01733589 Org: User:
Start: 11/30/12 End: 06/30/15 Due: 06/30/16

Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04266691 Org: User:
Start: 01/31/09 End: 06/30/19 Due: 06/30/20

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06254066 Org: User:
Start: 04/16/24 End: 12/31/28 Due: 12/31/29

Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions

Phase: N/A Priority: Normal
NCT ID: NCT03129412 Org: User:
Start: 04/14/17 End: 04/23/25 Due: 04/23/26

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Phase: N/A Priority: Normal
NCT ID: NCT06140576 Org: User:
Start: 11/30/23 End: 12/31/26 Due: 12/31/27

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT04691388 Org: User:
Start: 03/01/21 End: 12/01/24 Due: 12/01/25

Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients

Phase: N/A Priority: Normal
NCT ID: NCT06968091 Org: User:
Start: 05/16/25 End: 12/31/25 Due: 12/31/26

Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics

Phase: N/A Priority: Normal
NCT ID: NCT05985577 Org: User:
Start: 03/02/23 End: 07/30/24 Due: 07/30/25

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03276156 Org: User:
Start: 02/23/16 End: 02/22/18 Due: 02/22/19

Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection

Phase: N/A Priority: Normal
NCT ID: NCT01926483 Org: User:
Start: 03/31/13 End: 06/30/16 Due: 06/30/17

A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05705583 Org: User:
Start: 01/01/23 End: 12/31/25 Due: 12/31/26

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Phase: N/A Priority: Normal
NCT ID: NCT05669092 Org: User:
Start: 11/01/22 End: 12/31/25 Due: 12/31/26

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03756064 Org: User:
Start: 08/01/19 End: 07/31/21 Due: 07/31/22

Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03615170 Org: User:
Start: 07/19/17 End: 12/31/22 Due: 12/31/23

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01832948 Org: User:
Start: 01/31/13 End: 01/31/15 Due: 01/31/16

Anlotinib to Malignant Brainstem Glioma

Phase: N/A Priority: Normal
NCT ID: NCT04668508 Org: User:
Start: 11/24/20 End: 01/01/23 Due: 01/01/24

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05971199 Org: User:
Start: 11/23/21 End: 12/23/24 Due: 12/23/25

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04061772 Org: User:
Start: 08/12/19 End: 12/05/21 Due: 12/05/22